Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pancreatic Neuroendocrine Tumor (pNET)”

40 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 40 results

Testing effectiveness (Phase 2)Ended earlyNCT01628913
What this trial is testing

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Who this might be right for
Pancreatic Neuroendocrine Tumors (pNET)
Novartis Pharmaceuticals 62
Testing effectiveness (Phase 2)Ended earlyNCT01374451
What this trial is testing

Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

Who this might be right for
Islet Cell Tumor
Novartis Pharmaceuticals 160
Testing effectiveness (Phase 2)Ended earlyNCT05568017
What this trial is testing

Neoadjuvant PRRT With Y-90-DOTATOC in pNET

Who this might be right for
Pancreatic Neuroendocrine Tumor
European Institute of Oncology 11
Not applicableActive Not RecruitingNCT03043508
What this trial is testing

Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors)

Who this might be right for
Genetic MutationMEN1
M.D. Anderson Cancer Center 45
Testing effectiveness (Phase 2)Ended earlyNCT02273752
What this trial is testing

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerGastrinomaGlucagonoma+16 more
Emory University 2
Not applicableLooking for participantsNCT03048266
What this trial is testing

Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients

Who this might be right for
Multiple Endocrine Neoplasia
M.D. Anderson Cancer Center 629
Not applicableNot Yet RecruitingNCT07274657
What this trial is testing

Superb Microvascular Imaging (SMI) and Two-Dimensional Endoscopic Ultrasound Guided Shear Wave Elastography (2D-SWE-EUS) in Differential Diagnosis of Pancreatic Adenocarcinoma (PA) From Other Pancreatic Solid Lesions (PSLs) and Pancreatic neuroendocrinE Tumors (pNETs) Malignancy

Who this might be right for
Pancreas Adenocarcinoma (MSI-H)Pancreatic Neuroendocrine Tumors (pNET)
GCS Ramsay Santé pour l'Enseignement et la Recherche 150
Not applicableUnknownNCT03053999
What this trial is testing

Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)

Who this might be right for
Multiple Endocrine NeoplasiaPancreatic Neuroendocrine TumorsHyperparathyroidism
M.D. Anderson Cancer Center 53
Early research (Phase 1)Study completedNCT00161187
What this trial is testing

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Who this might be right for
Cancer
University of Medicine and Dentistry of New Jersey 37
Not applicableAvailableNCT07262970
What this trial is testing

Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor

Who this might be right for
Tumor-associated Hyperinsulinism (Tumor HI)
Rezolute
Early research (Phase 1)Study completedNCT00020579
What this trial is testing

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 75
Testing effectiveness (Phase 2)Looking for participantsNCT04074135
What this trial is testing

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

Who this might be right for
VHL Pancreatic Neuroendocrine TumorsVon Hippel-Lindau DiseaseNeuroendocrine Tumors
National Cancer Institute (NCI) 740
Very early researchEnded earlyNCT00499733
What this trial is testing

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Who this might be right for
Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19
Testing effectiveness (Phase 2)Study completedNCT02402062
What this trial is testing

Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Who this might be right for
Neuroendocrine TumorsPancreatic Neoplasms
Grupo Espanol de Tumores Neuroendocrinos 17
Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Testing effectiveness (Phase 2)Study completedNCT02132468
What this trial is testing

A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers

Who this might be right for
Neuroendocrine Tumors
Mateon Therapeutics 18
Testing effectiveness (Phase 2)Study completedNCT02279602
What this trial is testing

Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study

Who this might be right for
Neuroendocrine Tumors
Mateon Therapeutics 7
Early research (Phase 1)Study completedNCT00049296
What this trial is testing

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

Who this might be right for
Cancer
Case Comprehensive Cancer Center 26
Large-scale testing (Phase 3)Study completedNCT02246127
What this trial is testing

Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor

Who this might be right for
Neuroendocrine Tumors
Grupo Espanol de Tumores Neuroendocrinos 141
Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals
Load More Results
116